Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

Heart attacks increase heart failure risk. Dr. Teuteberg believes cardiac attacks damage the heart, making it pump less ...

No one wants to hear the words: "You have cancer." But about 1 in 8 American women will learn they have breast cancer, according to the Centers for Disease Control and Prevention. "Breast ...

ANI Pharmaceuticals (ANIP) announced results from the NEW DAY clinical trial of ILUVIEN, or fluocinolone acetonide intravitreal implant, 0.19 mg ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.

Chest strap vs. wrist-worn heart-rate monitors: Chest strap and wrist-worn heart-rate monitors are both used to measure heart rate, but they use different methods to provide readings.